Viral mimicry is thought to be an important mediator of tumor innate immunity in response to epigenetic therapies such as DNMT inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and EZH2 inhibitors (59, 60, 69, 80, 82, 83). Here, EZH2 is linked to neoplasm.